[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640174":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":18,"centralContacts":22,"locations":31,"responsibleParty":64,"collaborators":10,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":74,"sex":75,"minAge":76,"maxAge":10,"enrollmentInfo":77,"targetDuration":10,"studyType":80,"phases":10,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":34,"whyStopped":10,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"OptymEdge, LLC","INDUSTRY",[8,12,15],{"label":9,"type":10,"description":11,"interventionNames":10},"Normal\u002FNear Normal BCVA Range",null,"30 participants (33%) in the normal\u002Fnear-normal BCVA range (≤0.3 logMAR ≥70 letters); ≈20\u002F40 or better);",{"label":13,"type":10,"description":14,"interventionNames":10},"Mid-range BCVA","30 participants (33%) with mid-range BCVA (0.4-0.9 logMAR (36-69 letters); 20\u002F50 to 20\u002F200)",{"label":16,"type":10,"description":17,"interventionNames":10},"Low Vision BCVA","30 participants (33%) with low vision BCVA (≥ 1.0 logMAR (≤35 letters); worse than 20\u002F200) including off-chart acuities using protocol low-vision procedures).",[19],{"name":20,"affiliation":5,"role":21},"Ana Rita Santos, PhD","STUDY_DIRECTOR",[23,28],{"name":24,"role":25,"phone":26,"phoneExt":10,"email":27},"Tânia Mesquita, BSc","CONTACT","+351 239484348","emc.trials@oftalmologia.co.pt",{"name":29,"role":25,"phone":10,"phoneExt":10,"email":30},"Ana Claudia Rocha, BSc","abr@ess.ipp.pt",[32,50],{"facility":33,"status":34,"city":35,"state":10,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Espaço Medico de Coimbra","RECRUITING","Coimbra","3030-015","Portugal","PT",{"type":40,"coordinates":41},"Point",[42,43],-8.41996,40.20686,{"lat":43,"lon":42},[46,47],{"name":24,"role":25,"phone":26,"phoneExt":10,"email":27},{"name":48,"role":49,"phone":10,"phoneExt":10,"email":10},"Rufino Silva, PhD","PRINCIPAL_INVESTIGATOR",{"facility":51,"status":34,"city":52,"state":10,"zip":53,"country":37,"countryCode":38,"cosmosGeoPoint":54,"geoPoint":58,"contacts":59},"TBIO - Escola Superior de Saúde do Politécnico do Porto","Porto","4200-072",{"type":40,"coordinates":55},[56,57],-8.61097,41.1485,{"lat":57,"lon":56},[60,62],{"name":29,"role":25,"phone":61,"phoneExt":10,"email":30},"+351 22 206 1000",{"name":63,"role":49,"phone":10,"phoneExt":10,"email":10},"Catarina Mateus, PhD",{"type":65,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100640174","assessing-agreement-between-acuvera-capture-and-paper-based-methods-for-bcva-data-recording-in-ophthalmic-trials-100640174",false,"NCT07613580","Assessing Agreement Between Acuvera Capture and Paper-Based Methods for BCVA Data Recording in Ophthalmic Trials","An Observational Comparative Study Assessing Agreement Between Acuvera Capture and Paper-Based Methods for Best Corrected Visual Acuity (BCVA) Data Recording in Ophthalmic Clinical Trials","VALiCAPTURE","90 adult participants (≈180 eyes) with the following BCVA levels, will be included:\n\n* 30 participants (33%) in the normal\u002Fnear-normal BCVA range (≤0.3 logMAR ≥70 letters); ≈20\u002F40 or better);\n* 30 participants (33%) with mid-range BCVA (0.4-0.9 logMAR (36-69 letters); 20\u002F50 to 20\u002F200)\n* 30 participants (33%) with low vision BCVA (≥ 1.0 logMAR (≤35 letters); worse than 20\u002F200) including off-chart acuities using protocol low-vision procedures).\n\nInclusion Criteria:\n\n* Adults ≥18 years old\n* Able and willing to provide written informed consent\n* Capable of performing BCVA testing procedures according to study requirements\n* All BCVA ranges are eligible, including off-chart acuities (e.g., count fingers, hand motion, light perception) irrespective of the presence or absence of ocular disease.\n\nExclusion Criteria:\n\n* Any condition preventing reliable completion of BCVA testing (e.g., severe cognitive impairment, language barriers)\n* Inability or unwillingness to comply with study requirements\n* Non-ophthalmic condition that precludes safe or reliable testing (e.g., immediate post-operative systemic status preventing cooperation).\n* Any circumstance that, in the investigator's opinion, makes the eye\u002Fparticipant unsuitable for accurate BCVA testing or for completing both data-capture methods during the same visit.\n\nNumber of Sites: 2 ophthalmic clinical research centers Portugal)\n\nNumber of Countries: Portugal\n\nNumber of Visits: One study visit per participant\n\nDuration: 2 months\n\nParticipants will undergo BCVA testing at a single visit using both paper-based recording and electronic capture with Acuvera Capture. Testing order will be randomized to minimize bias. Paper data will be inserted by the examiners or study coordinator into the study eCRF. Electronic capture data will be exported directly from the app.",true,"ALL","18 Years",{"count":78,"type":79},90,"ESTIMATED","OBSERVATIONAL","Study Purpose: To evaluate the level of agreement between the Acuvera Capture application and traditional paper-based methods for recording Best Corrected Visual Acuity (BCVA) in ophthalmic clinical trials. The study aims to determine whether the electronic capture system provides equivalent or improved accuracy, consistency, and error reduction compared with paper-based recording, thereby supporting its potential adoption as a reliable method for BCVA data collection in clinical research.",[83],"Ophthalmopathy",[85,86,87],"BCVA","ETDRS Protocol","Electronic Capture","2026-05-21",{"date":90,"type":91},"2026-05-29","ACTUAL",{"date":93,"type":91},"2026-01-12",{"date":95,"type":79},"2026-06-30",{"name":5,"class":6},2]